ERBB2 and cancer: The patients with triple-negative cancer (20/38; 52.6%) and human epidermal growth factor receptor 2 (HER2)-enriched cancer (18/42; 42.9%) showed higher proportions of patients with axillary lymph node metastasis than those with luminal A cancer (19/64; 29.7%) and luminal B cancer (62/182; 34.1%), but only borderline statistical significance was shown (p = 0.081).